Compared to raw 2ME, the optimized formula exhibited enhanced anti-proliferative activity in MCF-7 breast cancer cells as evidenced by the down-regulation of cyclin D1 and inhibition of cell cycle progression. This evidence concerns the gene CCND1 and breast carcinoma.